All patients recruited in general practice are asked to fill out a patient questionnaire and examined:

- Collenbrander Mixed contrast card: testing near vision binocularly at 40 cm, using both 100% and 10% contrast.

- Amsler Test: Conducted for both eyes to check for central vision issues.

- Visual Field Test: Performed using the Donders method to assess peripheral vision, conducted for both eyes.

After tests in general practice, all patients undergo a comprehensive vision assessment at local optician shops, which include the following tests:

* Habitual Vision Testing: Near and distance vision with habitual glasses.
* Best Corrected Distance Vision: Monocular and binocular.
* Intraocular Pressure Measurement Assessed using air tonometry or Icare.
* Ocular Imaging: 3D peripapillary and macula optical coherence tomography (OCT) scans, and fundus photography.

A project ophtalmologist analyze patient-data from optometrists.

GP or GP nurse carry out the three vision tests. All patients visit optician shop collaborating with the project. An ophthalmologist review data from optometrists and provide an epicrisis to general practice. In case of acute conditions, the ophthalmologist is responsible for expedient treatment. If the patient needs further control by ophthalmologist within 12 month waiting time, general practice are responsible for referring the patient.

focus on vision impairment in older patients in general practice

Louise Uhre

Mads Kristensen

one Energy Resonance by Cutaneous Stimulation session performed before macrobiopsy

Energy Resonance by Cutaneous Stimulation session

Energy Resonance by Cutaneous Stimulation

Screening for neurodevelopmental disorders by an advanced practice nurse with Ages \& Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale

Screening for neurodevelopmental disorders by an advanced practice nurse

Marie VINCENTI, MD

Sophie Guillaumont, MD

Pascal Amedro, MD

For each patient, a blood sample will be taken at D0 before the CAR-T cells are injected then at D3, D7, D10, D30 after the injection. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis by effector immune cells (T lymphocytes, NK cells, CAR-T cells) and to define the phenotypic "signature" of trogocytosis.

Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in patients

For each healthy volunteer, a single blood sample will be taken at enrollment. Flow cytometry analysis will be performed on each sample on the day of collection to determine the level of trogocytosis of normal lymphocytes and NK cells.

Flow cytometry analysis to determine the level of trogocytosis by effector immune cells in volunteers

Valérie ROUILLE

Philippe GERAUD

This intervention is a 12-minute guided audio-visual relaxation intervention delivered at the baseline (Day 1) visit to determine the immediate effects of guided relaxation intervention on stress and pain in inpatients with sickle cell disease. The GR intervention also includes six video clips, ranging from 2 to 20 minutes in length to determine the short-term (Day 5) effects of guided relaxation intervention on stress and pain.

This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.

Guided Relaxation video clip

Attention Control Group: This intervention is a 12-minute sickle cell disease experience discussion. In this computer-based discussion, patients will discuss their experience of having sickle cell disease. The audio-taped questions and onscreen directions were programmed to be self-administered. Subjects' responses will be captured via the microphone so that Data Collectors are not involved in this discussion process, and it is equivalent to the guided relaxation activity.

This intervention is a 12-minute sickle cell disease experience discussion.

Sickle Cell Disease Experience Discussion

Adults on maintenance hemodialysis with renal anemia receive levocarnitine 1,000 mg IV immediately after each dialysis session, three times per week for 6 months, in addition to standard anemia management with erythropoiesis-stimulating agents (ESA) per unit protocol. Monthly assessments of hemoglobin, hematocrit, ESA dose, and erythropoietin responsiveness index (ERI).

1,000 mg levocarnitine IV (slow IV push or infusion per unit policy) post-hemodialysis, three times weekly for 6 months (\~72 doses). Administered in the dialysis unit in addition to usual ESA-based anemia care.

Levocarnitine Injection

Standard-of-care anemia management using recombinant human erythropoietin (ESA) per unit protocol. Typical initial dosing: 50-100 U/kg/week if Hb \<10 g/dL (in 2-3 doses/week); 50 U/kg/week if Hb 10-11 g/dL; 25-50 U/kg/week as maintenance if Hb 11-12 g/dL. ESA dose adjusted monthly using ERI and Hb/Hct targets (generally Hb 10-12 g/dL).

Usual ESA-Based Anemia Care

Standard anemia management with ESA per unit protocol without levocarnitine. Monthly assessments of hemoglobin, hematocrit, ESA dose, and ERI over 6 months.

After the second puncture, the local compression by thoracic bandage will be put in place.

The system being effective 7 days, it will be left in place between each visit. A visit will be made for all patients 7 days after the installation of the device. However, if necessary, an intermediate visit may be carried out.

During these visits, a puncture will be made according to the criteria mentioned above. The bandage will be renewed after each visit.

The device will be removed after 15 days without indication of a new puncture. The patient will be seen again between 10 and 15 days after the bandage is removed for a final evaluation.

1. \- Installation of a short stretch belt (urgo K2® kit)
2. \- Installation of a long stretch cohesive band providing additional pressure necessary to reach therapeutic pressure and maintain the device (urgo K2® kit).
3. \- Control of the pressure exerted by the bandage by the "KIKUHIME® Sub Bandge pressure Monitor" device

Compression by chest bandage urgo K2®

Every 7 days after the second puncture of a volume \> 250ml of seroma, the patients are examined by 2 practitioners. They define the indication of the puncture. The seroma is aspirated after a skin puncture with a needle connected with a Redon® drain.

punctures

After the second puncture, the patient will be seen at the same frequency as in the experimental arm.

The decision to perform a puncture will be made according to the same criteria and the follow-up conditions will be identical.

일반 진료에서 노인 환자의 시력 장애에 초점을 맞추다

피부 자극에 의한 에너지 공명

고급 실무 간호사에 의한 신경발달 장애 선별

환자의 효과기 면역 세포에 의한 트로고사이토시스 수준을 결정하기 위한 유세포 분석, 자원봉사자의 효과기 면역 세포에 의한 트로고사이토시스 수준을 결정하기 위한 유세포 분석

가이드 이완 영상 클립, 겸상 적혈구 빈혈 경험 토론

레보카르니틴 주사, 일반적인 ESA 기반 빈혈 치료

가슴 붕대 Urgo K2®에 의한 압박, 천자